1. Pink Sheet
  2. >>Geography

‘Substantial’ Discount Helps Zolgensma Win Access In UK

 
• By Francesca Bruce

The English and Scottish health technology appraisal bodies NICE and the Scottish Medicines Consortium have given the green light to Novartis/Avexis’ costly gene therapy, Zolgensma.

Morning in Jebel Shams, Oman
NHS England 'moved mountains' to strike Zolgensma deal • Source: Shutterstock

Novartis AG/Avexis’ Zolgensma (onasemnogene abeparvovec) is to be reimbursed on the National Health Service in both England and Scotland.

In England the product will be fast tracked to patients on the back of “evidence of exceptional benefit” before final...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Swissmedic Appoints Trivigno As New Agency Head From 2026

 
• By Anabel Costa-Ferreira

Vincenza Trivigno will take over as executive director from Raimund Bruhin, who is retiring after over seven years in the post.

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 
• By Eliza Slawther

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.